Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This is a research study to test whether a once-weekly injection of abatacept will prevent
the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form.To evaluate the
effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual
care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic
medication within 18 months of randomization in children with recent-onset limited JIA.